Skip to content

TAGline November 2024

  • Dorrit Walsh

This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.

Read more

Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short

  • Dorrit Walsh

TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

Read more

2023 Annual Report

  • Dorrit Walsh

We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.

Read more

Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding

  • Dorrit Walsh

In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.

Read more
Image that reads: 2024 HIV Cure Research Community Workshop. White text on a mostly green background

2024 Pre-CROI Community HIV Cure Research Workshop

  • Dorrit Walsh

The 2024 Pre-CROI Community HIV Cure Research Workshop took place on Saturday, March 2nd in Denver. This year’s workshop had a shorter format than in the past, but we plan to return to an all-day event in the future.

Read more

Story: CRISPR-Based Cure for HIV “could be months away”

  • Dorrit Walsh

October/November 2023 Media coverage: CRISPR gene therapy appears safe, but claims of an imminent HIV cure are premature - Liz Highleyman, AIDSMap, November 3, 2023 Cure for HIV could be months away as first three patients are injected with new…

Read more
Back To Top